Brain Cancer
Temporal Lobe Glioblastoma
Female, 70 years
Patient Internal 368807765
ICD-10 code
C71.2 Malignant Neoplasm of Temporal Lobe
Diagnosis (Incl. Metastases/Stage) and Year
November 2020
Glioblastoma of the Temporal Lobe, WHO IV, KI67 – up to 50%, IDH – wild type; MGMT – Methylated.
Previous Treatment
Radiation therapy, Chemotherapy (Temozolomide)
Prognosis and Survival Expectation
The prognosis remains poor, with a median survival of ~14 months from diagnosis.
Treatment Provided
Autologous DCV (6 doses) and CIK (4 doses) over a period of 5 months. Additionally, the patient received Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccines (PTAC) (10 Vaccines).
Patient Survival/Condition and Year
Date of Review: 01/12/2023
The patient has survived for 30 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Chemotherapy and Radiation Therapy, has extended patient survival by an
estimate of around 16 months.
